durvalumab,Oleclumab
Astrazeneca
['mbc', 'synergy', 'oleclumab', 'tnbc', 'bcsm']
#esmo22 mbc proffered paper session, from presents the results of synergy, the randomised ph2 investigator-initiated study in mtnbc: no improvement in cbr at 24 weeks with the addition of oleclumab (anti-cd73 moab) to chemo + anti-pdl1 in 1st line #bcsm 
Med Onc, Clinical Trials Development Leader @JulesBordet #BreastCancer #PrecisionMedicine. Views are mine https://t.co/PeEXATwb02